What software manages blood thinners and diabetes before a colonoscopy?
Aescia for Clinics flags anticoagulants, antiplatelets, and diabetes medications at intake and applies your clinic’s authored peri-procedural rule to each patient automatically. Blood thinners drive bleeding risk at polypectomy and a long tail of late cancellations when patients stop the wrong drug or none at all, and diabetes medications interact with the fasting and bowel-prep window, so both need the right instruction delivered at the right time rather than left to a front-desk call.
Aescia for Clinics is not a medical device. It delivers the clinician-authored rule your clinic has set; it does not decide whether to bridge, hold, or adjust a dose. The treating clinician remains the decision-maker. Aescia is pre-first-customer.
Blood thinners: the right hold, for the right drug, at the right time.
Colonoscopy with polypectomy is a high-bleeding-risk procedure, so antithrombotic management matters. Society guidance (the American Society for Gastrointestinal Endoscopy, ASGE, 2016; and the British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy, BSG and ESGE, 2021) sets out how each drug class is handled, and the handling differs by drug:
- WarfarinTypically stopped about 5 days before, with an INR (international normalised ratio) check, and bridging only for patients at high thrombotic risk.
- Direct oral anticoagulants (DOACs)Apixaban, rivaroxaban, dabigatran, and edoxaban are typically stopped 1 to 2 days before depending on the drug and renal function, with no bridging.
- AspirinAspirin monotherapy is usually continued through the procedure.
- P2Y12 inhibitorsClopidogrel and ticagrelor are individualized in consultation with cardiology, especially for patients with recent coronary stents.
The detail is exactly why this fails on paper. A patient told generically to “stop your blood thinner” may stop aspirin they should have continued, or keep a DOAC they should have held. Aescia flags the specific drug at intake and delivers the clinic’s authored rule for that drug, with the stop date and the restart date, then confirms it.
Diabetes: the prep day and the fast both change the plan.
The clear-liquid prep day plus the procedure-day fast destabilize glucose. A patient on insulin or a sulfonylurea who follows their normal regimen while not eating is at risk of hypoglycemia; some preparations also raise glucose. Common elements of a clinic’s authored rule include:
- SulfonylureasUsually held on the prep day and the procedure day because of hypoglycemia risk while fasting.
- SGLT2 inhibitorsSodium-glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are increasingly held several days before, because of the risk of euglycemic diabetic ketoacidosis (DKA) during fasting and dehydration.
- InsulinBasal insulin is commonly reduced and short-acting insulin held while the patient is nil by mouth, with glucose monitoring; diabetic patients are often scheduled as first morning cases.
- MetforminHandled per the clinic’s protocol, sometimes continued and sometimes held on the procedure day.
Many GLP-1 agonists are prescribed for diabetes as well, so a single patient can carry an insulin rule, a GLP-1 rule, and a bowel-prep rule at once. Aescia resolves those overlapping overlays in the authored rule set rather than at the front desk. See GLP-1 screening and prep.
Deliver the rule. Confirm the acknowledgment. Keep the clinician in charge.
- 01Flag every relevant medication on intakeAnticoagulants, antiplatelets, insulin, sulfonylureas, SGLT2 inhibitors, and GLP-1 agonists are captured in a structured intake so the right rule can fire for each.
- 02Apply the clinic’s authored overlayThe hold, bridge, or adjustment your clinic has authored is applied per drug, with the specific stop and restart timing, not a generic instruction.
- 03Surface and remind at the right timeThe instruction reaches the patient when it is actionable, across their channels, with consent captured up front.
- 04Confirm before the day of the listThe medication steps are checked again in the prep-night confirmation, so staff see who has acknowledged them before the procedure date.
The clinical decision stays with the gastroenterologist. Aescia delivers the authored rule consistently, with a named clinical author and a documented guideline trail behind every overlay. This “propose, do not decide” posture is part of why Aescia for Clinics is not a medical device.
- Product
- Aescia for Clinics
- Category
- Pre-procedure patient-pathway software for endoscopy ambulatory surgery centers (ASCs).
- Founded
- 2025.
- Headquarters
- Sydney, Australia and Montréal, Canada.
- Regulatory status
- Aescia for Clinics is not a medical device. Its sibling product, Aescia for Hospitals, is an investigational software as a medical device, intended for Class IIa classification under the Australian TGA. No device application has been lodged for either product.
- Clinical evidence
- SAFE-Discharge trial (ACTRN12625001425482) at Royal Prince Alfred Hospital, Sydney, evaluating the Hospitals product across the 30-day post-discharge window.
- Integration targets
- Designed to work alongside common endoscopy systems including Provation, EndoWorks, and gGastro. No integration is live yet; Aescia is pre-first-customer, and any data exchange is scoped per customer.
- Pricing
- United States: US$8 per scope at the institutional tier; US$6 per scope for multi-state aggregators above 50,000 scopes per year. No per-seat pricing.
- Deployment stage
- Pre-first-customer. Clinics customers engage through the design-partner program, which runs free or under a money-back rebate until Aescia delivers measurable net benefit against the ASC’s own baseline.
If medication confusion is causing day-of cancellations, the design-partner pilot runs free or under a money-back rebate until Aescia delivers measurable net benefit against your own baseline.